Human ABCC3 Stable Cell Line - MDCK

The ABCC3 gene encodes multidrug resistance-associated protein 3 (MRP3), a member of the ATP-binding cassette (ABC) transporter superfamily. Located on chromosome 17q21.3, MRP3 is an integrated membrane protein that acts as an ATP-dependent efflux pump, transporting a variety of organic anions. Unlike many other ABC transporters that export substrates into bile or the intestinal lumen, MRP3 is primarily located on the basolateral membrane (blood-facing membrane) of hepatocytes, enterocytes, and proximal renal tubular cells, where it facilitates the return of substrates to systemic circulation. Its endogenous substrates include glucuronide-bound bilirubin, bile sulfate, and various leukotrienes. In cases of cholestasis or hepatotoxic injury, hepatic ABCC3 expression is significantly upregulated via Nrf2 and PXR mediation. The ABCC3 pathway plays a crucial role in hepatoprotection, acting as a "safety valve" by reintroducing bile acids into the bloodstream for eventual renal excretion, preventing the toxic accumulation of bile acids in hepatocytes. Mutations or polymorphisms in ABCC3 are associated with altered drug responses and susceptibility to diseases such as Durbin-Johnson syndrome or Allagier syndrome.

The MDCK (Madin-Darby canine kidney) cell line, stably expressing human ABCC3, is the gold standard model for studying polarized transmembrane transport and pharmacokinetics. By overexpressing human ABCC3, researchers can precisely measure the basolateral efflux kinetics of candidate drugs, a crucial component of ADME (absorption, distribution, metabolism, and excretion). In the pharmaceutical industry, this product is used for drug profiling. It is essential for identifying potential drug interactions (DDIs) involving MRP3 transporters, which can significantly alter the safety and efficacy of combination therapies. In oncology, the ABCC3-MDCK model is used to study the mechanisms of multidrug resistance (MDR) because MRP3 has been shown to efflux multiple chemotherapeutic agents, including methotrexate, teniposide, and etoposide. This cell line provides a powerful platform for screening chemosensitizers that can inhibit MRP3-mediated efflux, thereby increasing the intracellular concentration and efficacy of anticancer therapies in drug-resistant tumors.